Xeris Biopharma Holdings (XERS) Intangibles (2021 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Intangibles came in at $85.4 million in Q1 2026, down 11.27% YoY from $96.2 million in Q1 2025, and down 3.08% on a QoQ basis from $88.1 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Intangibles (2021 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 6 years of Intangibles data on file, last reported at $85.4 million in Q1 2026.
- Quarterly Intangibles fell 11.27% year-over-year to $85.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85.4 million (down 11.27% YoY) and the FY2025 annual result came in at $88.1 million, down 10.96% from the prior year.
- Intangibles eased to $85.4 million in Q1 2026, from $88.1 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $128.7 million in Q1 2022 to a low of $85.4 million in Q1 2026.
- A 5-year average of $107.1 million and a median of $107.1 million in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2022 — Intangibles retreated 8.25% — and 2026, when it slipped 11.27%.
- Tracing XERS's Intangibles over 5 years: stood at $120.6 million in 2022, then declined by 8.99% to $109.8 million in 2023, then decreased by 9.88% to $98.9 million in 2024, then decreased by 10.96% to $88.1 million in 2025, then slipped by 3.08% to $85.4 million in 2026.
- The last three Intangibles figures came in at $85.4 million (Q1 2026), $88.1 million (Q4 2025), and $90.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 3.45 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 918.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 21.28 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 13.68 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 2.23 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 3.20 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 1.12 Bn |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 82.66 Mn |
| Mar 31, 2026 | 85.37 Mn |
| Dec 31, 2025 | 88.08 Mn |
| Sep 30, 2025 | 90.79 Mn |
| Jun 30, 2025 | 93.50 Mn |
| Mar 31, 2025 | 96.21 Mn |
| Dec 31, 2024 | 98.92 Mn |
| Sep 30, 2024 | 101.63 Mn |
| Jun 30, 2024 | 104.34 Mn |
| Mar 31, 2024 | 107.05 Mn |
| Dec 31, 2023 | 109.76 Mn |
| Sep 30, 2023 | 112.48 Mn |
| Jun 30, 2023 | 115.19 Mn |
| Mar 31, 2023 | 117.90 Mn |
| Dec 31, 2022 | 120.61 Mn |
| Sep 30, 2022 | 123.32 Mn |
| Jun 30, 2022 | 126.03 Mn |
| Mar 31, 2022 | 128.74 Mn |
| Dec 31, 2021 | 131.45 Mn |